Breakthrough in Tuberculosis Treatment: Sorfequiline Trials Show Promise

Recent trial results suggest that sorfequiline, a new antibiotic for tuberculosis (TB), could significantly enhance cure rates and reduce treatment duration by several months. The World Health Organization (WHO) reported that in 2022, approximately 10.7 million individuals were diagnosed with TB, leading to 1.23 million deaths, highlighting the disease as a major global public health issue. The WHO's annual report emphasized that progress in combating TB is hindered by funding cuts and insufficient advancements toward the UN's goal of eliminating TB as a public health threat by the end of the decade.

The Guardian

The trial, conducted by researchers from the TB Alliance, involved 309 participants across 22 sites in South Africa, the Philippines, Georgia, Tanzania, and Uganda. All participants had "drug-sensitive" TB, which can be treated with standard drug regimens. However, researchers believe that sorfequiline may also benefit patients with drug-resistant TB. Dr. Maria Beumont, vice-president of TB Alliance, noted that the new regimen allows for immediate treatment initiation without waiting for diagnostic results, potentially streamlining patient care.

The Guardian

Dr. William Brumskine, a clinical research site leader at the Aurum Institute in South Africa, expressed optimism that the universal regimen could improve overall care by reducing the frequency of clinic visits, thereby allowing healthcare providers to focus more on individual patient needs.

The Guardian

Historically, patients with drug-resistant TB faced arduous treatment regimens lasting 18 months or more, with only a 50% cure rate. The introduction of a new gold-standard treatment in 2019 improved this to a 90% success rate within six months. The potential of sorfequiline to further enhance treatment outcomes has generated excitement among researchers and healthcare professionals.

The Guardian

Despite the promising results, some experts have raised concerns about the universal application of sorfequiline. Dr. Kavindhran Velen, chief scientific officer at the International Union against Tuberculosis and Lung Disease, cautioned that while a more effective treatment could increase patient compliance and reduce contagion, it might also discourage investments in essential innovations such as laboratory testing. He emphasized the need for careful consideration to avoid overexposing patients to unnecessary treatments.

The Guardian

The TB Alliance plans to initiate a phase-3 clinical trial for sorfequiline in 2026, aiming to validate its efficacy and safety further. As the medical community awaits these results, the potential for sorfequiline to transform TB treatment remains a focal point of discussion among health professionals.

The Guardian

• “She said: “I can just put you on a treatment while I’m waiting to understand exactly what your situation is.” — Dr. Maria Beumont, Vice-President, TB Alliance

The Guardian

• “The hope of having a universal regimen that is shorter, that has less side-effects, is you will have less individuals coming in for clinic visits [and so] the health care providers will have more time to give individual care to patients,” — Dr. William Brumskine, Clinical Research Site Leader, Aurum Institute

The Guardian

• “It’s incredible when you start getting these little anecdotes from the sites [such as]: ‘This patient got cured so fast.” — Dr. Maria Beumont, Vice-President, TB Alliance

The Guardian

• “taking a hammer to an ant [for patients who could be treated with gentler drugs]. We don’t want to overexpose an individual to treatment that is not necessarily needed.” — Dr. Kavindhran Velen, Chief Scientific Officer, International Union against Tuberculosis and Lung Disease

The Guardian